Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib

BACKGROUND: In advanced renal cell carcinoma (RCC), sunitinib and sorafenib tyrosine kinase inhibitors (TKI) are associated with several clinical side effects, with no definitive established data concerning their clinical impact. METHODS: From June 2006 to June 2008, main clinical TKI-induced toxici...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Fiore, F, Rigal, O, Ménager, C, Michel, P, Pfister, C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3251894/
https://www.ncbi.nlm.nih.gov/pubmed/22095228
http://dx.doi.org/10.1038/bjc.2011.507

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3251894/
https://www.ncbi.nlm.nih.gov/pubmed/22095228
http://dx.doi.org/10.1038/bjc.2011.507

Ejemplares similares